SIGA Technologies, Inc.

NasdaqGM:SIGA Stock Report

Market Cap: US$447.0m

SIGA Technologies Valuation

Is SIGA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SIGA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SIGA ($6.25) is trading below our estimate of fair value ($33.35)

Significantly Below Fair Value: SIGA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SIGA?

Key metric: As SIGA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SIGA. This is calculated by dividing SIGA's market cap by their current earnings.
What is SIGA's PE Ratio?
PE Ratio5.2x
EarningsUS$85.71m
Market CapUS$446.99m

Price to Earnings Ratio vs Peers

How does SIGA's PE Ratio compare to its peers?

The above table shows the PE ratio for SIGA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.5x
BTMD biote
26.2x64.8%US$221.3m
PAHC Phibro Animal Health
54.4x60.0%US$962.0m
COLL Collegium Pharmaceutical
10.9x22.0%US$959.4m
INVA Innoviva
18.6xn/aUS$1.2b
SIGA SIGA Technologies
5.2xn/aUS$447.0m

Price-To-Earnings vs Peers: SIGA is good value based on its Price-To-Earnings Ratio (5.2x) compared to the peer average (27.5x).


Price to Earnings Ratio vs Industry

How does SIGA's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-7.1%US$3.76b
NDOI Endo
0.6xn/aUS$1.91b
PROC Procaps Group
1.2xn/aUS$59.68m
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.59m
SIGA 5.2xIndustry Avg. 20.1xNo. of Companies12PE01224364860+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SIGA is good value based on its Price-To-Earnings Ratio (5.2x) compared to the US Pharmaceuticals industry average (19.9x).


Price to Earnings Ratio vs Fair Ratio

What is SIGA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SIGA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SIGA's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies